Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail. Rezo’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) developed by Nevan Krogan, Ph.D., director of QBI and a co-founder and chief executive officer of Rezo. Chemistry pioneer and inventor of leading drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI).
